Transforming growth factor-beta1 gene expression and cyclosporine A-induced gingival overgrowth: a pilot study.
OBJECTIVE
The relationship between gingival overgrowth (GO) induced by cyclosporine A (CsA) and transforming growth factor-beta1 (TGF-beta1) remains unclear. The aims of the present study were to evaluate TGF-beta1 gene expression under different immunosuppressive treatments and its association with TGF-beta1 gene functional polymorphism and GO in renal transplant recipients.


METHODS
The study included 98 CsA-treated renal transplant recipients (with and without GO) and 44 tacrolimus-treated transplant patients (without GO). TGF-beta1 mRNA expression was measured using a real-time quantitative polymerase chain reaction assay. The levels were correlated with TGF-beta1 gene polymorphisms at codons 10 and 25, with different immunosuppressive treatment and GO.


RESULTS
The level of TGF-beta1 gene expression was insignificantly lower in the CsA-treated group compared with the tacrolimus group, and significantly lower in the group with GO compared with patients without GO. In tacrolimus- and CsA-treated patients, but not in patients with GO, the level of TGF-beta1 gene expression was associated with functional phenotypes of TGF-beta1. The incidence, degree and extent of GO were higher in recipients with lower TGF-beta1 gene expression.


CONCLUSIONS
Lower level TGF-beta1 gene expression, not functional polymorphism, in patients treated with CsA may be considered to be a risk factor for GO.
Radwan-Oczko
Małgorzata
M
Department of Periodontology, Silesian Piasts University of Medicine, Wrocław, Poland. malgorzata.oczko@poczta.onet.pl
Boratyńska
Maria
M
Zietek
Marek
M
Dobosz
Tadeusz
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D015870:Gene Expression; D019214:Gingival Overgrowth / Q000097:blood / Q000139:chemically induced* / Q000235:genetics; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D016559:Tacrolimus / Q000627:therapeutic use; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics
D007166:Immunosuppressive Agents; D053773:Transforming Growth Factor beta1; D016572:Cyclosporine; D016559:Tacrolimus